Regulation of potassium channels in coronary arterial smooth muscle by endothelium-derived vasodilators

Hypertension. 1997 Jan;29(1 Pt 2):262-7. doi: 10.1161/01.hyp.29.1.262.

Abstract

Recent studies have suggested that coronary endothelial cells produce and release nitric oxide (NO), prostaglandin I2, and epoxyeicosatrienoic acids (EETs). These endothelium-derived vasodilators play an important role in the control of coronary vascular tone. However, the mechanism by which these endothelium-derived vasodilators cause relaxation of coronary arterial smooth muscle has yet to be determined. This study characterized and compared the effects of NO, prostaglandin I2, and 11,12-EET on the two main types of potassium channels in small bovine coronary arterial smooth muscle: the large conductance Ca(2+)-activated K+ channels (KCa) and 4-aminopyridine-sensitive delayed rectifier K+ channels (Kdrf). In cell-attached patches, nonoate, an NO donor, activated both KCa and Kdrf channels. The open probability of both KCa and Kdrf channels increased 10- to 25-fold when nonoate was added to the bath at concentrations of 10(-6) to 10(-4) mol/L. 11,12-EET (10(-8) to 10(-4) mol/L) also increased the activity of the KCa channels in a concentration-dependent manner, but it had no effect on the activity of the Kdrf channels, even in the highest concentration studied (10(-4) mol/L). In contrast to the effect of 11,12-EET, iloprost, a prostaglandin I2 analogue (10(-6) to 10(-4) mol/L), produced a concentration-dependent increase in the activity of Kdrf channels without affecting the KCa channels. In conclusion, all three endothelium-derived vasodilators act to open potassium channels; however, the channel types that they affect are different. NO activates both KCa and Kdrf channels; 11,12-EET activates only the KCa channels; and prostaglandin I2 activates only the Kdrf channels.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 8,11,14-Eicosatrienoic Acid / analogs & derivatives*
  • 8,11,14-Eicosatrienoic Acid / pharmacology
  • Animals
  • Cattle
  • Coronary Vessels / drug effects*
  • Coronary Vessels / metabolism
  • Epoprostenol / pharmacology*
  • Membrane Potentials / drug effects
  • Muscle, Smooth, Vascular / drug effects*
  • Muscle, Smooth, Vascular / metabolism
  • Nitric Oxide / pharmacology*
  • Peptides / pharmacology
  • Potassium Channels / drug effects*
  • Potassium Channels / metabolism
  • Vasodilation / physiology*

Substances

  • Peptides
  • Potassium Channels
  • Nitric Oxide
  • 11,12-epoxy-5,8,14-eicosatrienoic acid
  • iberiotoxin
  • Epoprostenol
  • 8,11,14-Eicosatrienoic Acid